2 Microbiome-Based Potential Therapies for IBD Enter Early Testing, Biomica Announces

2 Microbiome-Based Potential Therapies for IBD Enter Early Testing, Biomica Announces
Biomica announced the start of preclinical studies to test the anti-inflammatory abilities of two of its microbiome-based therapies for inflammatory bowel disease (IBD). The company's potential microbe treatments aim to restore the proper diversity of microbes in the gut, with the goal of reducing inflammation in people with IBD. “We believe our drug candidate consortia designed to target the underlying causes of inflammation associated with Inflammatory Bowel Disease will provide a new form of therapy for this chronic and devastating condition,” Elran Haber, PhD, Biomica's CEO, said in a press release IBD — which includes ulcerative colitis and Crohn’s disease — are chronic inflammatory diseases of the digestive tract. Primarily, anti-inflammatory medications such as corticosteroids are used to reduce swelling. However, these medications do not address the underlying causes of IBD. Given that the connection between the microbiome and IBD is well known, Biomic
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *